Hematological abnormalities are common among HIV-infected patients. Of those, bone marrow changes such as anemia and pancytopenia can be observed in advanced HIV disease. However, experimental evidence for those manifestations in animal immunodeficiency virus infection models has been limited. In the present study,
Introduction
Human immunodeficiency virus type 1 (HIV-1) infection is associated with hematological changes 1 . Antiretroviral therapy (ART) is effective on the control of viremia and the treatment of AIDS. However, some patients fail to show sufficient Tcell immune restoration despite being aviremic during treatment 2 . Such immunological nonresponsiveness can be associated with immune activation and/or bone marrow impairment 3, 4 . Bone marrow abnormalities, such as dysplasia and abnormal hematopoietic cell development, have frequently been observed in HIV-infected individuals 5 . Therefore, a method of protecting the whole hematopoietic cell populations from HIV would be desirable for preventing immunological/hematological disorders associated with HIV infection.
Transcriptional gene silencing (TGS) occurs through small non-coding RNAs that
direct epigenetic changes such as DNA methylation and heterochromatin formation.
TGS was first described in plants 6 . Since then, the application of TGS in humans has been investigated for the development of new therapeutic agents 7 . For example, previous reports showed sustained, profound, highly specific suppression of viral replication by siRNA-and short hairpin RNA (shRNA)-induced TGS of HIV-1 and simian immunodeficiency virus in various in vitro models, through a mechanism that results in chromatin compaction [8] [9] [10] [11] [12] [13] [14] . Because HIV-1 has identical long terminal repeats (LTRs) at the 5′ and 3′ ends of the integrated virus, any promoter-targeted siRNA can potentially act through post-transcriptional gene silencing (PTGS). With the lead candidate called PromA, it was found that the contribution of PTGS is limited 8 .
In the previous collaborative study including in vivo animal experiments, a lentiviral delivery system was used to express the previously described shRNA PromA targeting the HIV-1 promoter region to transduce human PBMCs, whereby an antiviral effect of the TGS produced by this construct on HIV-1 infection in vivo was demonstrated using NOD/SCID/Jak3 null (NOJ) mice 15 transplanted with the lentivirally transduced PBMCs 13 . In the present study, we tested whether the TGS through the shRNA (shPromA) may be applied to more profound gene therapy such as genemodified hematopoietic stem cell transplantation to replace patients' immune system to an HIV-resistant one. Humanized mouse models have been characterized for tissue distribution of human hematopoietic cells and HIV infection of those cells 16 . To take better advantage of the NOJ-based humanized mouse model, we transplanted irradiated newborn NOJ mice with human cord-derived CD34 + cells as described previously 17 .
We demonstrate that the generated hematopoietic/immune cells, especially CD4 + T cells, are resistant to the replication of the challenged HIV-1 JRFL in vivo. We also show that bone marrow CD34 + cells expressing shPromA may be better protected and preserved after HIV infection.
Materials and Methods
Virus stocks. Stocks of HIV-1 JRFL were produced by transfection of 293T cell line with the molecular clone DNA pJRFL. After the transfection, the culture supernatant was collected and virus titers were determined using an HIV p24 Enzyme-Linked
ImmunoSorbent Assay (ELISA) kit (ZeptoMetrix, NY, USA).
Cells.
Umbilical cord blood (UCB) samples from healthy newborn infants were collected at Fukuda Hospital, Kumamoto, Japan following informed consent. Cord blood mononuclear cells were isolated using Pancoll (PAN-Biotech GmbH, Aidenbach, Germany) and by density gradient centrifugation. CD34 + cells were labelled and selected using human CD34 micro beads and LS columns (Miltenyi Biotec, NSW, Australia). The purity was constantly above 92 % on flow cytometric analysis. 
Production of lentivirus.

Results
Cord-derived CD34 + cells were efficiently transduced with lentivirus expressing the shPromA customized for HIV-1 JRFL
The siRNAs PromA and PromA M2 were described previously 13 . 
CD34 + cells transduced with lentivirus expressing shPromA showed colony forming capability in vitro relevant to untransduced CD34 + cells
In order to confirm the quality of CD34 + cells in terms of their potential for differentiation, we performed colony formation assays using methylcellulose culture containing cytokines (Fig. S2) . Colonies expressing shPromA were detected by checking the GFP fluorescence emission on fluorescence microscopy ( Fig S2A) . No significant difference was found in the colony forming units between untransduced samples and shPromA-treated samples (Fig. S2B) . After counting colonies, the methylcellulose culture cells were collected, and analyzed by flow cytometry. The untransduced CD34 + cells and shPromA-treated CD34 + cells showed similar CD33/CD14 differentiation patterns (Fig. S2C) . Also, there was no obvious skew in the expression of CD33 or CD14 between GFP + and GFP − cells in the shPromA-treated sample. (Fig. S2C) . (monocytes). There was no obvious skew in the expression of GFP among all the phenotypes of cells tested ( Fig. 2A and C) .
Transplantation of irradiated newborn
Suppression of viral replication after HIV-1 JRFL challenge observed in NOJ mice
transplanted with shRNA PromA-expressing CD34 + cells
The 2 groups of mice (PromA and CD34) were challenged with HIV-1 JRFL 14-16 weeks after transplantation (Fig. 3) . Peripheral blood was collected at weeks 1 and 2 post-challenge. Mice were sacrificed at week 2 and splenocytes and bone marrow cells (from the left femur) were collected for further analysis (Fig. 3) . Intracellular HIV Gag p24 expression levels were measured in PBMC (weeks 1 and 2), splenocytes (week 2), and bone marrow cells (week 2). There were significant differences in HIV p24 + frequencies in CD3 + CD8 -T cells at weeks 1 and 2, indicating the impact of PromA on suppression of HIV replication ( Fig. 4A and B, Fig. S4 ). Cell-associated HIV DNA/RNA copy numbers in splenocytes (week 2) relative to human GAPDH were measured by quantitative PCR/RT-PCR. In group PromA, the average relative RNA copy number was lower than in group CD34, while relative DNA copy numbers were significantly higher ( Fig. 4C left and middle) . The ratios of the HIV RNA expression levels to the HIV DNA levels were calculated. The average RNA/DNA ratio in group
PromA was more than 10 times lower than that in group CD34 (Fig. 4C right) S5 , Table 1 ). In PBMC, human CD45 + percentages were significantly lower in group
PromA than in group CD34 (Fig. S5A) . The peripheral blood human CD45 + cell counts also showed significant difference at week 1 (Fig. S5B) . However, the blood CD45+ cell counts at week 2 were not significantly different between the 2 groups (Fig. S5B) .
Moreover, the CD45+ cell counts in spleens and bone marrows were much higher in group PromA than in group CD34 ( Table 1 ). The reasons for these discrepancies are not clear.
There was a marked decline in the splenocyte CD4 + CCR5 + frequencies in group CD34 at week 2 compared to the uninfected control group, presumably due to their depletion following HIV replication ( Fig. 5A and B) . On the other hand, the mice in group PromA showed preserved splenocyte CD4 + CCR5 + T-cell frequencies, supporting the protective effect of PromA against the CCR5-tropic challenge strain of HIV-1 ( Fig.   5A and B) . Similar results were found by the analysis of PBMCs sampled at week 2 post challenge showed the similar results (Fig. S6) . To better clarify the protective effect of PromA on human hematopoietic cells in HIV infection, we analyzed bone marrow CD34 + cells (Fig. 5C and D) . At week 2 post challenge, CD34 + cells were severely depleted in group CD34 compared to the uninfected control group (Fig. 5D ).
The CD34 + frequencies in group PromA were significantly higher than those in CD34 group (Fig. 5D ), indicating that shPromA was associated with protection of bone marrow cells including hematopoietic stem/progenitor cells (HSPCs). The calculation of bone marrow CD34 + cell counts showed similar results. (Fig. S7A) . We further analyzed shRNA (GFP) expression levels in the bone marrow cells of group PromA mice. Interestingly, CD34 + cells had greater GFP + frequencies than CD45 + cells (Fig.   S7B ), implicating the possible role for shPromA in protection of CD34 + cells from HIV infection.
In vitro generated PromA-expressing macrophages showed resistance to HIV-1 JRFL replication in vitro
In parallel with the HIV challenge experiment with the humanized mice, the effect of shPromA on suppression of HIV replication was tested with macrophages generated in vitro from cord-derived CD34 + cells. PromA-expressing (GFP + ) macrophages with the typical fried-egg shapes were successfully generated (Fig. 6A) (Fig. 6B) . The in vitro generated macrophages were infected with HIV-1 JRFL . Five days after infection, HIV replication levels, measured as intracellular HIV p24 + percentages, were compared between autologous untransduced, shPromA-M2-transduced, and shPromA-transduced macrophages. As shown in Fig 6C and D, macrophages transduced with shPromA showed suppression of HIV replication.
Discussion
One of the challenges with the current standard HIV therapies is that there is no effective way so far to repair the immune system that is supposed to be already partly broken at the time of treatment initiation even without manifestation of AIDS 21 . Gene therapy of HSPCs has been of great interest, because this could possibly recover the lost naïve/memory T-cell repertoire, which then would enable re-immunization of the individual against pathogens including HIV 22 . The most successful cases so far are those using the knockout or knockdown of CCR5, a coreceptor used by those strains of HIV-1 infecting memory CD4 + T cells 23 . In addition, researchers have been finding other host and non-host targets that would make the host cells more resistant to HIV replication 24 . The PromA region in the HIV genome has proved to be among safe and powerful non-host targets 25 .
In the present study, we performed transplantation of newborn NOJ mice with Fig. 2A-C , Table   1 ). This suggests that the off-target effects associated with the expression of PromA do not interfere with differentiation of hematopoietic cells in vivo 13 . The method we tested here is thus promising and also supporting the previous reports showing that retroviral transduction does not alter the immune functions 26 .
In the following HIV-1 JRFL challenge experiment, the mice engrafted with shPromA-transduced cells showed suppression of HIV replication (Fig. 4) and preservation of CD4 + CCR5 + T cells ( Fig. 5A and B) , which was relevant to the previous in vivo results using adult NOJ mice transplanted with shPromA-transduced PBMCs 13 .
It was also confirmed here that the mice in group PromA also showed preserved human CD34 + cells in the bone marrow ( Fig. 5C and D, Fig. S7 ). This implicates the advantages of the anti-HIV gene therapy of CD34 + HSPCs over the identical gene therapy of PBMC, because in the former, shPromA can even confer protection of
HSPCs from HIV-1 as well as their differentiation processes 21, 27 . As multiple types of hematopoietic progenitor cells can harbor CCR5-or CXCR4-tropic virus for a long time 28 , the expression of an anti-HIV modality in all of those cell types may be highly effective on protection of the hematopoietic system in HIV-infected patients.
The limited duration of the collaboration, the limited number of mice available, the limited technical expertise in the field of humanized mouse models, and the lack of In addition to the control problems, the use of the PC3 facility in Japan was allowed for a strictly limited duration of time. Therefore, the HIV challenge study was planned as a 2-week acute infection experiment with injection of a high dose HIV-1 JRFL per animal.
However, a chronic infection study starting from injection of a low dose HIV-1 JRFL should be more desirable to address the long-term effect of the shPromA-expressing hematopoietic/immune system upon control of persistent HIV infection that is most commonly observed with HIV-infected patients. This will further help clarify whether
PromA is able to support preservation of bone marrow CD34 + cells and their functions for a long time 29 . These future plans will better address whether the gene therapy approach with TGS may restore the hematopoietic system functions of HIV-infected patients and extend the periods of symptom-free lives.
In summary, even with those limitations, the present study demonstrates that the gene therapy of HSPCs with shPromA targeting a non-host, non-coding gene sequence may be beneficial for preservation of the hematopoiesis potential in the bone marrow 16 . This is a remarkable step toward a clinical application of TGS, including combination of PromA and other modalities e.g. targeting of CCR5 and antiretroviral therapies. (Fig. 3) . N.D.: not determined.
